Results 31 to 40 of about 92,873 (239)
PLoS ONE, 2019 Glioblastoma is the leading malignant glioma with a poor prognosis. This study aimed to investigate the antitumor effects of natural killer cells in combination with temozolomide as the standard chemotherapeutic agent for glioblastoma.
Yoshitaka Tanaka +12 more
doaj +1 more source
T-type Ca2+ Channels: T for Targetable [PDF]
, 2018 In the last decade TTCC have been unveiled as key regulators of cancer cells biology and thus have been proposed as chemotherapeutic targets. Indeed in vitro and in vivo studies indicate that TTCC pharmacological blockers have a negative impact on the ...
Cantí Nicolás, Carles +5 more
core +2 more sources
Frontiers in Oncology, 2022 Glioblastoma is a highly lethal grade of astrocytoma with very low median survival. Despite extensive efforts, there is still a lack of alternatives that might improve these prospects. We uncovered that the chemotherapeutic agent temozolomide impinges on
Sweta Parik +26 more
doaj +1 more source
Southern Clinics of Istanbul Eurasia, 2019 INTRODUCTION[|]This study was performed to determine whether adjuvant temozolomide and 45 Gy/15 fr hypofractionated radiotherapy (RT) can be used to shorten the treatment duration in glioblastoma multiforme (GBM) patients with poor prognostic factors ...
Fuzuli Tuğrul +3 more
doaj +1 more source
Cost-effectiveness of [18F] fluoroethyl-L-tyrosine for temozolomide therapy assessment in patients with glioblastoma [PDF]
, 2019 Background and Purpose: Glioblastomas are the most aggressive of all gliomas. The prognosis of these gliomas, which are classified as grade IV tumors by the World Health Organization (WHO), is poor.
Baguet, Tristan +3 more
core +1 more source
Restoration of Sensitivity in Chemo [PDF]
, 2013 Glioblastoma (GBM) is the most common and aggressive brain tumor in adults. Despite multimodal treatments including surgery, chemotherapy and radiotherapy the prognosis remains poor and relapse occurs regularly.
Boxhammer, Veronika +10 more
core +1 more source
Fluids and Barriers of the CNS, 2018 Background The blood–brain barrier (BBB) severely limits the entry of systemically administered drugs including chemotherapy to the brain. In rodents, regadenoson activation of adenosine A2A receptors causes transient BBB disruption and increased drug ...
Sadhana Jackson +12 more
doaj +1 more source
BMC Neurology, 2023 Background Lymphoproliferative disorder represents a heterogeneous clinicopathological spectrum characterized by uncontrolled proliferation of lymphocytes. Immunodeficiency is a major trigger of its development.
Daisuke Sato +7 more
doaj +1 more source
A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatinum-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology. [PDF]
, 2017 In the present study, we evaluated the efficacy of trabectedin (TRAB) and temozolomide (TEM) compared to cisplatinum (CDDP) on a patient-derived orthotopic xenogrraft (PDOX) of a lung-metastasis from an osteosarcoma of a patient who failed CDDP therapy ...
Dry, Sarah M +15 more
core +1 more source
Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model. [PDF]
, 2017 Relapsed osteosarcoma is a recalcitrant tumor. A patient's cisplatinum (CDDP)-resistant relapsed osteosarcoma lung metastasis was previously established orthotopically in the distal femur of mice to establish a patient-derived orthotopic xenograft (PDOX)
Dry, Sarah M. +23 more
core +1 more source